Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod.

A 52-year-old woman with cutaneous T-cell lymphoma (CTCL) presented to the dermatology clinic for treatment. She had a more than 10-year history of episodic dry, itchy patches over her trunk and extremities. Previous biopsy specimens obtained from the patches revealed histopathologic changes typical of CTCL. Treatment with a number of topical steroid preparations and topical nitrogen mustard and carmustine had been ineffective. On physical examination, she had 2 clinically similar, welldemarcated patches with mild erythema and scale involving less than 10% of her total body surface area (stage IA). She had no evidence of systemic involvement.

[1]  J. Berth-Jones,et al.  Imiquimod: a novel treatment for lentigo maligna , 2000, The British journal of dermatology.

[2]  G. Schuler,et al.  Topical imiquimod treatment of a cutaneous melanoma metastasis. , 2000, Journal of the American Academy of Dermatology.

[3]  D. Sauder,et al.  Immunomodulatory and pharmacologic properties of imiquimod. , 2000, Journal of the American Academy of Dermatology.

[4]  R. Amonette,et al.  The Use of Imiquimod 5% Cream for the Treatment of Superficial Basal Cell Carcinomas in a Basal Cell Nevus Syndrome Patient , 2000, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[5]  K. Beutner,et al.  Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. , 1999, Journal of the American Academy of Dermatology.

[6]  R. Miller,et al.  Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. , 1999, Cellular immunology.

[7]  R. Dummer,et al.  Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). , 1996, Blood.

[8]  F. Gasparro,et al.  Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma: relevance to mechanism of therapeutic action. , 1996, The Journal of investigative dermatology.

[9]  R. Edelson,et al.  Photopheresis for the treatment of cutaneous T-cell lymphoma. , 1995, Hematology/oncology clinics of North America.

[10]  T. Testerman,et al.  Cytokine induction by the immunomodulators imiquimod and S‐27609 , 1995, Journal of leukocyte biology.

[11]  G. Trinchieri,et al.  IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. , 1995, Journal of immunology.

[12]  A. Rook,et al.  Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. , 1992, The Journal of investigative dermatology.

[13]  L. Walsh,et al.  Extracorporeal Photochemotherapy Induces the Production of Tumor Necrosis Factor-α by Monocytes: Implications for the Treatment of Cutaneous T-Cell Lymphoma and Systemic Sclerosis , 1992 .

[14]  R. Coffman,et al.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. , 1986, Journal of immunology.

[15]  D. Byar,et al.  Prognostic variables in mycosis fungoides , 1981, Cancer.

[16]  A. Ahmed,et al.  Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. , 1975, Annals of internal medicine.